BRIEF published on 10/23/2026 at 07:05, 14 days 11 hours ago BB Biotech AG Reports Strong Interim Financial Results Biotechnology Investment Company Net Profit BB Biotech AG Interim Report
BRIEF published on 10/23/2026 at 07:05, 14 days 11 hours ago BB Biotech's Q3 2026: Gains and Strategic Portfolio Moves AI Integration Net Profit BB Biotech Q3 2026 Drug Approvals
PRESS RELEASE published on 10/23/2026 at 07:00, 14 days 11 hours ago EQS-Adhoc: BB Biotech AG publishes its interim report BB Biotech AG publishes interim report for the first nine months of 2026, reporting a net profit of CHF 605 mn. Third quarter profit at CHF 175 mn Investment Company Q3 Results Net Profit BB Biotech AG Interim Report
PRESS RELEASE published on 10/23/2026 at 07:00, 14 days 11 hours ago BB Biotech Q3 2026: Positive returns, clinical progress and active portfolio redeployment BB Biotech AG reports positive returns, clinical progress, and active portfolio redeployment in Q3 2026, with a 5.6% NAV return and 6.5% share price return in CHF BB Biotech AG Returns Clinical Progress Q3 2026 Portfolio Redeployment
BRIEF published on 07/28/2026 at 15:25, 3 months 9 days ago Edison Research Analyzes BB Biotech's Robust Q2 Performance Investment Strategy Portfolio Expansion Market Outlook BB Biotech Q2 2026 Results
PRESS RELEASE published on 07/28/2026 at 15:20, 3 months 9 days ago Edison issues report on BB Biotech (BION) Edison issues favorable report on BB Biotech (BION) Q226 results, highlighting NAV growth, portfolio adjustments, and revised payout policy, supporting positive outlook for biotechnology investing Biotechnology Edison Report BB Biotech Q226 Results
BRIEF published on 07/24/2026 at 07:05, 3 months 13 days ago BB Biotech AG Reports Interim Gains and Adjusts Dividend Policy Dividend Policy Investment Portfolio Interim Report BB Biotech Net Gain
BRIEF published on 07/24/2026 at 07:05, 3 months 13 days ago BB Biotech Q2 2026: Robust NAV Performance Amid Strategic Investments Portfolio Diversification Dividend Policy Strategic Investments M&A Activity Biotechnology Performance
PRESS RELEASE published on 07/24/2026 at 07:00, 3 months 13 days ago EQS-Adhoc: BB Biotech AG publishes its interim report and revises its dividend policy BB Biotech AG publishes its interim report for the first half of 2026, reporting a net gain and revising its dividend policy. Details at www.bbbiotech.ch Financial Results Investment Company Dividend Policy BB Biotech AG Interim Report
PRESS RELEASE published on 07/24/2026 at 07:00, 3 months 13 days ago BB Biotech Q2 2026: Strong NAV outperformance driven by disciplined stock selection and portfolio positioning BB Biotech AG reports strong NAV outperformance in Q2 2026, driven by disciplined stock selection and portfolio positioning, new investments, and revised dividend policy Dividend Policy BB Biotech AG Stock Selection Q2 2026 NAV Outperformance
Published on 11/06/2026 at 13:00, 5 hours 34 minutes ago Alaska Energy Metals Achieves High Extraction Rates of Metals from Hydromet Testing, Nikolai Nickel Project, Alaska
Published on 11/06/2026 at 12:30, 6 hours 4 minutes ago Relevant Gold Receives Expanded Drilling Approvals for the Lewiston Project in Wyoming
Published on 11/06/2026 at 12:30, 6 hours 4 minutes ago Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
Published on 11/06/2026 at 05:15, 13 hours 19 minutes ago Valeo and QNX Unveil A New Smart Camera Platform at CIIE, Secures Multiple Design Wins
Published on 11/06/2026 at 17:41, 53 minutes ago Turkiye Garanti Bankasi A.S.: Daily Share Buyback Transactions
Published on 11/06/2026 at 14:50, 3 hours 44 minutes ago New UN guide keeps people in charge of AI in smart cities
Published on 11/06/2026 at 17:54, 40 minutes ago Disclosure of Share Capital and Voting Rights as of October 31, 2026
Published on 11/06/2026 at 17:35, 59 minutes ago Disclosure of the number of shares and the total number of voting rights as of October 31, 2026
